Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 15/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12782944 | 0.93 | SCN3A (0.62) | SCN3ASCN9ASCN5AALDH1A1PKM | |
| SCHEMBL12845590 | 0.90 | SCN3A (0.71) | SCN3ASCN9AALDH1A1PKM | |
| SCHEMBL12845725 | 0.88 | SCN3A (0.59) | SCN3ASCN9ASCN5AALDH1A1PKM | |
| SCHEMBL12845594 | 0.88 | SCN3A (0.57) | SCN3AALDH1A1PKM | |
| SCHEMBL12845646 | 0.85 | SCN3A (0.55) | SCN3ASCN9ASCN5AALDH1A1PKM | |
| SCHEMBL2075384 | 0.85 | SCN3A (0.57) | SCN3ASCN9A | |
| SCHEMBL12845556 | 0.84 | SCN3A (0.51) | SCN3ASCN9ASCN5AALDH1A1PKM | |
| SCHEMBL12783030 | 0.84 | SCN3A (0.83) | SCN3ASCN9ASCN5AALDH1A1PKM | |
| SCHEMBL12845613 | 0.83 | SCN3A (0.53) | SCN3ASCN9ASCN5A | |
| SCHEMBL12782829 | 0.82 | SCN3A (0.62) | SCN3ASCN9ASCN5AALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362032-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110059965-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7786137-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786137-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | CACNA1C, CACNA1B, CACNA1D | SCN3A 17/4885SCN9A 92/4885SCN5A 79/4885 |
| US-20110059965-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | CACNA1C, CACNA1B, CACNA1D | SCN3A 17/4885SCN9A 92/4885SCN5A 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.